Tenofovir Alafenamide Fumarate (TAF) Effect on Residual Intrathecal Immune Activation
Status:
Completed
Trial end date:
2018-07-15
Target enrollment:
Participant gender:
Summary
Many HIV-infected individuals on effective antiretroviral therapy with suppressed HIV RNA
levels in blood as well as in cerebrospinal fluid have signs of low-level intrathecal
inflammation. Our aim is to study if changing the nucleoside backbone in an antiretroviral
regimen can decrease the residual intrathecal immune activation.